Ibrutinib 140mg Capsules (Nitib)

No, Ibrutinib 140mg capsule should not be taken to prevent cancer. It is a prescription medication specifically approved for treating certain types of blood cancers like chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and others. It is not meant for cancer prevention and can cause serious side effects if taken without medical need.
Using Ibrutinib without a proper diagnosis and supervision can be harmful. If you are concerned about your cancer risk, talk to your doctor about appropriate screening tests, lifestyle changes, and preventive care options.

Ibrutinib 140mg capsule can be taken with other medications, but caution is very important because it can interact with many drugs, which may increase side effects or reduce its effectiveness.
Medications to watch out for:

Blood thinners (e.g., warfarin, aspirin, clopidogrel): Increases risk of bleeding

Antifungals (e.g., ketoconazole, itraconazole)

Antibiotics (e.g., clarithromycin, erythromycin)

Antivirals (e.g., ritonavir)

Stomach acid reducers (e.g., omeprazole, ranitidine)

Certain anti-seizure medications (e.g., phenytoin, carbamazepine)

Herbal supplements (especially St. John’s Wort)

What you should do:

Always inform your doctor about all prescription drugs, over-the-counter medicines, and supplements you are taking.

Do not start or stop any medication without your doctor’s approval while on Ibrutinib.

Your doctor may adjust doses or monitor you more closely to avoid harmful interactions.

The duration of Ibrutinib 140mg capsule treatment varies from person to person and depends on:

The type and stage of cancer being treated

How well your body is responding to the medication

Any side effects or complications

Your overall health condition

In most cases: Ibrutinib is taken daily and continuously until the disease progresses or side effects become too severe. Some patients may need to take it long-term for ongoing control of the cancer.
Do not stop or change the dose without your doctor’s advice, even if you start feeling better or your test results improve. Your doctor will decide the right time to stop, adjust, or continue treatment based on regular monitoring.

It’s best to limit or avoid alcohol while taking Ibrutinib.
Here's why:

Increased side effects: Alcohol can worsen side effects like dizziness, tiredness, or liver problems.

Liver strain: Both alcohol and Ibrutinib are processed by the liver, so drinking can put extra stress on it

Bleeding risk: Alcohol can thin the blood, and Ibrutinib already increases bleeding risk—together, this could be dangerous.

What to do:

If you want to drink occasionally, talk to your doctor first to make sure it’s safe in your case.

Always stay well-hydrated and avoid heavy drinking.

Being cautious with alcohol helps you stay safer during treatment.

No, Ibrutinib 140mg capsule cannot cure all types of cancer. What it is used for: Ibrutinib is specifically approved to treat certain types of blood cancers, including:

Chronic lymphocytic leukemia (CLL)

Mantle cell lymphoma (MCL)

Waldenström’s macroglobulinemia (WM)

Small lymphocytic lymphoma (SLL)

Chronic graft-versus-host disease (cGVHD)

What it does: Ibrutinib controls the disease and may slow its progression, but it is not a cure. It helps patients live longer and with better quality of life, but long-term use is often needed.
For other types of cancers, especially solid tumors (like breast, lung, or colon cancer), Ibrutinib is not effective or approved for use. Always follow your doctor's guidance on treatment options based on the specific type of cancer.

Yes, you should use effective contraception while taking Ibrutinib. Here's why:

Ibrutinib may harm an unborn baby if taken during pregnancy.

Both men and women should use reliable birth control during treatment and for at least 1 month after the last dose.

For women:

Do not get pregnant while on Ibrutinib.

Talk to your doctor about safe and effective birth control methods.

For men:

Use contraception during treatment and for a month afterward to avoid exposing a partner to the drug through pregnancy.

Also, avoid breastfeeding during treatment and for at least 1 week after the final dose, as it's not known if Ibrutinib passes into breast milk.

Ibrutinib mechanism of action

Ibrutinib works by stopping Btk from fully activating by stopping its autophosphorylation at Tyr-223. This interference stops the next step in activating the BCR pathway, which stops the growth, proliferation, and survival of cancerous B cells.

ibrutinib life expectancy

In clinical trials, the typical duration of imbruvica therapy has averaged around 41 months, with a range of 2 to 51 months. After discontinuation of Imbruvica treatment, the average survival duration was 8 months.

Zanubrutinib vs Ibrutinib

In a cohort of 652 patients with a median follow-up of 29.6 months, zanubrutinib demonstrated superiority over ibrutinib in terms of progression-free survival. The hazard ratio for disease progression or death was 0.65 (95% confidence interval [CI], 0.49 to 0.86; P = 0.002), as reported by the investigators, and these findings were consistent with those of an independent review committee.

1. Indications and Usage Lists the diseases ibrutinib is approved to treat, such as:

Chronic lymphocytic leukemia (CLL)

Mantle cell lymphoma (MCL)

Waldenström's macroglobulinemia (WM)

Marginal zone lymphoma (MZL)

Chronic graft-versus-host disease (cGVHD)

2. Dosage and Administration

Recommended dose and frequency

Special instructions for missed doses

Dose adjustments for liver impairment or side effects

3. Dosage Forms and Strengths

Available as capsules or tablets (commonly 140 mg, 280 mg, etc.)

4. Contraindications

Situations where ibrutinib should not be used (e.g., known allergy)

Warnings and Precautions

Risk of bleeding, infections, atrial fibrillation, hypertension, second primary malignancies

6. Adverse Reactions (Side Effects)

Most common side effects: diarrhea, fatigue, musculoskeletal pain, rash

Serious side effects: bleeding, infections, heart rhythm problems

7. Drug Interactions

Interactions with CYP3A inhibitors/inducers (like ketoconazole or rifampin)

8. Use in Specific Populations

Pregnancy, breastfeeding, pediatric, and geriatric use

9. Clinical Pharmacology

How the drug works (mechanism of action as a BTK inhibitor)

Absorption, metabolism, and excretion details

10. Clinical Studies

Summary of key clinical trials supporting approval

11. Storage and Handling

Recommended storage conditions and packaging

Ibrutinib is a targeted therapy used to treat Chronic Lymphocytic Leukemia (CLL), including CLL with 17p deletion, which is a high-risk genetic subtype. How Ibrutinib Works in CLL Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor. It blocks BTK, a protein that plays a crucial role in the survival and proliferation of B-cells — the type of cells that become cancerous in CLL.
By inhibiting BTK:

It disrupts cancer cell signaling

Slows or stops the growth of CLL cells

Promotes apoptosis (cell death)

✅ FDA-Approved Uses in CLL 1. First-line treatment for CLL/SLL (small lymphocytic lymphoma)
2. Treatment of CLL with 17p deletion
3. Used alone or in combination with other drugs such as:

Obinutuzumab (anti-CD20 antibody)

Rituximab (another anti-CD20 antibody)

💊 Typical Dosing for CLL

420 mg orally once daily

Taken until disease progression or unacceptable toxicity

Should be taken at the same time every day with a glass of water (do not crush/chew)

⚠️ Common Side Effects

Diarrhea

Fatigue

Muscle and joint pain

Bruising and bleeding

Infections (especially upper respiratory)

Atrial fibrillation

Hypertension

Rash

🔄 Monitoring During Treatment Doctors monitor:

Blood counts

ECG (for heart rhythm)

Signs of infection or bleeding

Blood pressure

🧬 CLL with 17p Deletion

Patients with del(17p) often respond poorly to chemotherapy

Ibrutinib is especially effective in this group, making it a preferred first-line treatment

Ibrutinib has a well-known side effect profile that healthcare providers monitor closely. It’s important to understand that while some side effects are mild and manageable, others can be serious and require medical attention.
Common Side Effects These occur in many patients but are often manageable:

Diarrhea

Fatigue

Muscle/bone pain

Nausea

Bruising

Rash

Decreased appetite

Cough or URTI

ibrutinib brand name​

Tybriva 140mg capsule

Nitib 140mg capsule

Bdbrut 140mg capsule

Ibrunat 140mg capsule

Ibrushil 140mg capsule

Ibrutinib 140mg is used to treat various types of blood cancers, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia. It helps stop cancer cell growth by blocking BTK proteins.

Common side effects of Ibrutinib 140mg include diarrhea, fatigue, muscle pain, rash, and bleeding. Serious effects may include infections and irregular heartbeat. Always follow your doctor’s advice.

The dosage depends on the type of cancer being treated. Typically, ibrutinib is taken once daily, and the total dose may involve multiple 140mg capsules. Dosage should be prescribed by a specialist.

Yes, Ibrutinib 140mg capsules are available online through authorized exporters and pharmacies. Always ensure you're purchasing from a licensed and reputable supplier.

Yes, Ibrutinib is one of the leading treatments for chronic lymphocytic leukemia (CLL). It helps slow disease progression and is often used as first-line or second-line therapy.